OBJECTIVE: To compare the effectiveness of antihyperglycemic therapies in type 2 diabetic patients with poor glycemic control (baseline glycosylated hemoglobin [HbA1C] > 8%). STUDY DESIGN: Longitudinal (cohort) study. METHODS: Study patients were 4775 type 2 diabetic patients who initiated new antihyperglycemic therapies and maintained them for up to 1 year. The study setting was Kaiser Permanente Northern California Medical Group, an integrated, prepaid, healthcare delivery organization. Treatment regimens were 1 or more of the following: insulin, thiazolidinediones, sulfonylureas, biguanides (metformin), or other less frequently used options (including meglitinides or alpha-glucosidase inhibitors). RESULTS: In this cohort, the mean HbA1C was 9.9% when therapy was initiated. Within 1 year, there was a drop of 1.3 percentage points in the mean HbA1C (to 8.6%), and 18% of new initiators achieved HbA1C values of < or = 7%. After adjusting for baseline clinical differences, the proportion of patients treated to goal was greatest among those receiving thiazolidinediones in combination (24.6%-25.7%) or a regimen of metformin and insulin (24.9%), while the least success was experienced by those receiving sulfonylureas alone (12.5%) or insulin-sulfonylureas regimens (10.9%). The probability of achieving the target goal was most strongly predicted by the level of glycemic control before initiation, but patient behaviors (eg, frequent self-monitoring, lower rates of missed appointments) also were strongly associated with greater levels of control. CONCLUSION: Overall, therapy initiation resulted in an impressive population-level benefit. However, since most new initiators still had not achieved good control within 12 months, careful monitoring and prompt therapy intensification remain important.
OBJECTIVE: To compare the effectiveness of antihyperglycemic therapies in type 2 diabeticpatients with poor glycemic control (baseline glycosylated hemoglobin [HbA1C] > 8%). STUDY DESIGN: Longitudinal (cohort) study. METHODS: Study patients were 4775 type 2 diabeticpatients who initiated new antihyperglycemic therapies and maintained them for up to 1 year. The study setting was Kaiser Permanente Northern California Medical Group, an integrated, prepaid, healthcare delivery organization. Treatment regimens were 1 or more of the following: insulin, thiazolidinediones, sulfonylureas, biguanides (metformin), or other less frequently used options (including meglitinides or alpha-glucosidase inhibitors). RESULTS: In this cohort, the mean HbA1C was 9.9% when therapy was initiated. Within 1 year, there was a drop of 1.3 percentage points in the mean HbA1C (to 8.6%), and 18% of new initiators achieved HbA1C values of < or = 7%. After adjusting for baseline clinical differences, the proportion of patients treated to goal was greatest among those receiving thiazolidinediones in combination (24.6%-25.7%) or a regimen of metformin and insulin (24.9%), while the least success was experienced by those receiving sulfonylureas alone (12.5%) or insulin-sulfonylureas regimens (10.9%). The probability of achieving the target goal was most strongly predicted by the level of glycemic control before initiation, but patient behaviors (eg, frequent self-monitoring, lower rates of missed appointments) also were strongly associated with greater levels of control. CONCLUSION: Overall, therapy initiation resulted in an impressive population-level benefit. However, since most new initiators still had not achieved good control within 12 months, careful monitoring and prompt therapy intensification remain important.
Authors: Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri Journal: Diabetes Res Clin Pract Date: 1995-05 Impact factor: 5.602
Authors: Matthew D McElvany; Priscilla H Chan; Heather A Prentice; Elizabeth W Paxton; Mark T Dillon; Ronald A Navarro Journal: Clin Orthop Relat Res Date: 2019-06 Impact factor: 4.176
Authors: Howard H Moffet; Nancy Adler; Dean Schillinger; Ameena T Ahmed; Barbara Laraia; Joe V Selby; Romain Neugebauer; Jennifer Y Liu; Melissa M Parker; Margaret Warton; Andrew J Karter Journal: Int J Epidemiol Date: 2008-03-07 Impact factor: 7.196
Authors: Andrew J Karter; Melissa M Parker; Howard H Moffet; Ameena T Ahmed; Julie A Schmittdiel; Joe V Selby Journal: Health Serv Res Date: 2009-06-03 Impact factor: 3.402
Authors: Michelle T Vo; Connie S Uratsu; Karen R Estacio; Andrea Altschuler; Eileen Kim; Stacey E Alexeeff; Alyce S Adams; Julie A Schmittdiel; Michele Heisler; Richard W Grant Journal: J Gen Intern Med Date: 2019-02-11 Impact factor: 5.128
Authors: Connie Mah Trinacty; Alyce S Adams; Stephen B Soumerai; Fang Zhang; James B Meigs; John D Piette; Dennis Ross-Degnan Journal: J Gen Intern Med Date: 2007-09-01 Impact factor: 5.128
Authors: Andrew J Karter; Howard H Moffet; Jennifer Liu; Melissa M Parker; Ameena T Ahmed; Alan S Go; Joe V Selby Journal: Am J Manag Care Date: 2007-11 Impact factor: 2.229
Authors: Jennifer Elston Lafata; Andrew J Karter; Patrick J O'Connor; Heather Morris; Julie A Schmittdiel; Scott Ratliff; Katherine M Newton; Marsha A Raebel; Ram D Pathak; Abraham Thomas; Melissa G Butler; Kristi Reynolds; Beth Waitzfelder; John F Steiner Journal: J Gen Intern Med Date: 2016-02 Impact factor: 5.128
Authors: Shari Danielle Bolen; Eric Bricker; T Alafia Samuels; Hsin-Chieh Yeh; Spyridon S Marinopoulos; Maura McGuire; Marcela Abuid; Frederick L Brancati Journal: Diabetes Care Date: 2008-10-17 Impact factor: 19.112
Authors: Laura N McEwen; Dori Bilik; Susan L Johnson; Jeffrey B Halter; Andrew J Karter; Carol M Mangione; Usha Subramanian; Beth Waitzfelder; Jesse C Crosson; William H Herman Journal: Diabetes Care Date: 2009-02-19 Impact factor: 19.112